Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Takeda is the lead sponsor of 77 current clinical trials in our USA, China, UK, Ireland and India registers. 55 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Zasocitinib, Vedolizumab and Elritercept. The most-studied condition is Crohn's Disease.

Company profile on this site (news, sites, medicines, approvals): Takeda Ireland (IE) →

ClinicalTrials.gov trials by status

Recruiting5571%
Not yet open23%
Active, closed2026%

Trials by phase

Phase 33545%
Phase 21621%
Observational1317%
Phase 468%
Phase 1/245%
Phase 2/323%
Phase 111%

Clinical trials sponsored by Takeda

77 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions NCT07422480 · Myelodysplastic Syndrome, Anemia Drugs: Elritercept, Epoetin Alfa	Phase 3	Recruiting	2026-05	Ireland, UK, USA, India, China
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India NCT06831370 · Hodgkin Lymphoma Drugs: Brentuximab Vedotin, Dacarbazine, Doxorubicin	Phase 4	Recruiting	2024-08	India
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions NCT05816382 · Narcolepsy Type 1 Drug: TAK-861	Phase 2/3	Recruiting	2023-04	USA
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions NCT06499285 · Myelodysplastic Syndromes Drug: Elritercept	Phase 3	Recruiting	2025-05	Ireland, UK, USA, India
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease NCT06100289 · ClinicalTrials.gov ↗ · Ulcerative Colitis, Crohn's Disease Drug: Vedolizumab	Phase 3	Recruiting	2025-01	Ireland, USA
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis NCT05037760 · Myelofibrosis Drugs: Elritercept, Ruxolitinib	Phase 2	Recruiting	2021-12	UK
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD) NCT05582993 · ClinicalTrials.gov ↗ · Von Willebrand Disease (VWD) Drug: Advate	Phase 3	Recruiting	2024-11	Ireland, UK, USA
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein NCT05677971 · ClinicalTrials.gov ↗ · Alpha1-Antitrypsin Deficiency Drug: Fazirsiran	Phase 3	Recruiting	2023-03	Ireland, UK, USA
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia NCT06948318 · Immune Thrombocytopenic Purpura (ITP) Drug: Mezagitamab	Phase 3	Recruiting	2025-08	UK, USA, China
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease NCT06227910 · ClinicalTrials.gov ↗ · Crohn's Disease Drugs: Upadacitinib, Vedolizumab	Phase 3	Recruiting	2025-01	Ireland, UK, USA
A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems NCT06512454 · ClinicalTrials.gov ↗ · Alpha1-Antitrypsin Deficiency	Observational	Recruiting	2024-09	Ireland, UK, USA
A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC) NCT07229911 · Healthy Volunteers, Primary Sclerosing Cholangitis	Phase 1	Recruiting	2026-01	USA
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) NCT06405087 · ClinicalTrials.gov ↗ · Ulcerative Colitis, Crohn's Disease Drug: Vedolizumab	Phase 3	Recruiting	2025-10	Ireland, USA
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib NCT07623161 · ClinicalTrials.gov ↗ · Myelofibrosis, Anemia Drug: Elritercept	Phase 3	Recruiting	2026-09	Ireland, UK, USA, India
A Study of TAK-755 in Adults With Acute Ischemic Stroke NCT07392450 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke Drug: TAK-755	Phase 2	Recruiting	2026-05	UK, USA, India, China
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease NCT05837897 · ClinicalTrials.gov ↗ · Crohn's Disease Drug: Vedolizumab	Phase 3	Recruiting	2023-06	China
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) NCT06952699 · Narcolepsy Type 2 Drug: TAK-360	Phase 2	Recruiting	2025-05	USA, China
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery NCT05156983 · Coagulation Disorder	Phase 3	Recruiting	2022-08	USA
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy NCT06963827 · ClinicalTrials.gov ↗ · Kidney Disease Drug: Mezagitamab	Phase 3	Recruiting	2025-07	UK, USA, China
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease NCT06233461 · ClinicalTrials.gov ↗ · Crohn's Disease Drug: Zasocitinib	Phase 2	Recruiting	2024-03	UK, USA, China
A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation NCT06243731 · ClinicalTrials.gov ↗ · Cytomegalovirus (CMV), Kidney Disease, Kidney Failure	Observational	Recruiting	2025-11	UK
A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease NCT07403968 · ClinicalTrials.gov ↗ · Crohn's Disease Drug: Zasocitinib	Phase 2	Recruiting	2026-08	UK
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) NCT04779320 · ClinicalTrials.gov ↗ · Crohn's Disease (CD) Drug: Vedolizumab	Phase 3	Recruiting	2022-02	UK, USA, China
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia NCT06722235 · ClinicalTrials.gov ↗ · Immune Thrombocytopenic Purpura (ITP) Drug: Mezagitamab	Phase 3	Recruiting	2025-02	UK, USA, China
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines NCT06671496 · ClinicalTrials.gov ↗ · Psoriatic Arthritis Drug: Zasocitinib	Phase 3	Recruiting	2025-03	UK, USA, China
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT) NCT05319353 · ClinicalTrials.gov ↗ · Cytomegalovirus (CMV) Drug: Maribavir	Phase 3	Recruiting	2023-11	UK, USA, China
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) NCT06095128 · Ulcerative Colitis Drugs: Tofacitinib, Vedolizumab	Phase 4	Recruiting	2024-06	USA
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo NCT07108283 · Nonsegmental Vitiligo Drug: Zasocitinib	Phase 2	Recruiting	2025-11	USA, China
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) NCT06165341 · ClinicalTrials.gov ↗ · Alpha1-Antitrypsin Deficiency Drug: Fazirsiran	Phase 3	Recruiting	2024-03	UK, USA
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma NCT06980480 · ClinicalTrials.gov ↗ · Multiple Myeloma, Secondary Immunodeficiency	Phase 3	Recruiting	2026-01	UK, USA
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease NCT06045754 · ClinicalTrials.gov ↗ · Crohn's Disease Drugs: Adalimumab, Ustekinumab, Vedolizumab	Phase 4	Recruiting	2024-04	USA
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis NCT07286058 · ClinicalTrials.gov ↗ · Psoriatic Arthritis Drug: Zasocitinib	Phase 3	Recruiting	2026-03	USA, China
A Study of TAK-360 in Adults With Idiopathic Hypersomnia NCT06812078 · ClinicalTrials.gov ↗ · Idiopathic Hypersomnia Drug: TAK-360	Phase 2	Recruiting	2025-02	USA
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis NCT07250802 · ClinicalTrials.gov ↗ · Plaque Psoriasis Drug: Zasocitinib	Phase 3	Recruiting	2025-12	USA, China
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) NCT05442567 · ClinicalTrials.gov ↗ · Ulcerative Colitis, Crohn's Disease Drug: Vedolizumab	Phase 3	Recruiting	2023-05	UK, USA, China
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) NCT06764615 · ClinicalTrials.gov ↗ · Crohn's Disease, Ulcerative Colitis Drug: Zasocitinib	Phase 2	Recruiting	2025-05	USA, China
A Study of TAK-505 in Adults With Solid Tumors NCT07436728 · ClinicalTrials.gov ↗ · Malignant Solid Tumors	Phase 1/2	Recruiting	2026-05	USA
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer NCT06562543 · ClinicalTrials.gov ↗ · Colorectal Cancer Drug: Fruquintinib	Phase 4	Recruiting	2025-01	USA
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) NCT06798012 · ClinicalTrials.gov ↗ · Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)	Phase 2	Recruiting	2025-05	USA
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) NCT06747351 · ClinicalTrials.gov ↗ · Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)	Phase 3	Recruiting	2025-05	USA
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa NCT07244263 · ClinicalTrials.gov ↗ · Hidradenitis Suppurativa Drug: Zasocitinib	Phase 2	Recruiting	2026-01	USA, China
A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey) NCT05561647 · ClinicalTrials.gov ↗ · Short Bowel Syndrome (SBS)	Observational	Recruiting	2013-08	USA
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines NCT06671483 · ClinicalTrials.gov ↗ · Psoriatic Arthritis Drug: Zasocitinib	Phase 3	Recruiting	2025-03	USA
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) NCT04419649 · ClinicalTrials.gov ↗ · Myelodysplastic Syndromes, Cytopenia Drug: Elritercept	Phase 2	Recruiting	2020-08	USA
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections NCT06439342 · ClinicalTrials.gov ↗ · Cytomegalovirus (CMV) Drug: Maribavir	Phase 3	Recruiting	2024-12	China
A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care NCT06538064 · ClinicalTrials.gov ↗ · Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)	Observational	Recruiting	2025-04	USA
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer NCT07217301 · ClinicalTrials.gov ↗ · IO-resistant sqNSCLC	Phase 3	Recruiting	2025-11	USA, China
A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy) NCT07633301 · ClinicalTrials.gov ↗ · Narcolepsy Type 1 Drug: TAK-360	Phase 2	Recruiting	2026-06	USA, China
A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome NCT07319832 · ClinicalTrials.gov ↗ · Short Bowel Syndrome (SBS)	Observational	Recruiting	2026-03	China
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting NCT06581328 · ClinicalTrials.gov ↗ · Ulcerative Colitis, Crohn's Disease Drug: Vedolizumab	Phase 4	Recruiting	2025-03	USA
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia NCT07646678 · ClinicalTrials.gov ↗ · Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2 Drug: TAK-360	Phase 2/3	Recruiting	2026-06	USA, China
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors NCT07205718 · ClinicalTrials.gov ↗ · Advanced or Metastatic Solid Tumors	Phase 1/2	Recruiting	2025-11	USA
A Study of Prucalopride in Breastfeeding Women With Constipation NCT04838522 · ClinicalTrials.gov ↗ · Chronic Idiopathic Constipation (CIC)	Observational	Recruiting	2022-03	USA
A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD) NCT07129343 · ClinicalTrials.gov ↗ · Von Willebrand Disease (VWD) Drug: Advate	Phase 3	Recruiting	2025-10	China
A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease NCT07187440 · ClinicalTrials.gov ↗ · Fabry Disease	Observational	Recruiting	2025-11	China
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant NCT07613359 · Antibody-Mediated Rejection (AMR) Drug: Mezagitamab	Phase 2	Not yet open	2026-09	USA, China
A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease NCT07250815 · ClinicalTrials.gov ↗ · Ulcerative Colitis, Crohn's Disease	Observational	Not yet open	2026-09	USA
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer NCT02716116 · Carcinoma, Non-Small-Cell Lung Drug: TAK-788	Phase 1/2	Active, closed	2016-06	UK, USA, China
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis NCT06254950 · Ulcerative Colitis Drug: Zasocitinib	Phase 2	Active, closed	2024-03	UK, USA, China
A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) NCT05469789 · ClinicalTrials.gov ↗ · Hereditary Angioedema (HAE)	Observational	Active, closed	2023-06	UK
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura NCT04683003 · ClinicalTrials.gov ↗ · Thrombotic Thrombocytopenic Purpura (TTP) Drug: TAK-755	Phase 3	Active, closed	2021-04	UK, USA, China
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis NCT06550076 · ClinicalTrials.gov ↗ · Plaque Psoriasis Drug: Zasocitinib	Phase 3	Active, closed	2024-09	UK, USA, China
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia NCT03589326 · ClinicalTrials.gov ↗ · Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Drugs: Cytarabine, Dexamethasone, Imatinib	Phase 3	Active, closed	2018-10	USA, China
An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease NCT05899673 · ClinicalTrials.gov ↗ · Alpha1-Antitrypsin Deficiency Drug: Fazirsiran	Phase 3	Active, closed	2023-08	UK, USA
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy NCT07363720 · ClinicalTrials.gov ↗ · Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy Drug: TAK-861	Phase 3	Active, closed	2026-01	USA
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations NCT04129502 · ClinicalTrials.gov ↗ · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Drugs: Carboplatin, Cisplatin, Pemetrexed	Phase 3	Active, closed	2020-01	UK, USA, China
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis NCT03221036 · ClinicalTrials.gov ↗ · Moderately to Severely Active Ulcerative Colitis Drug: Vedolizumab	Phase 3	Active, closed	2017-08	China
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) NCT05020015 · ClinicalTrials.gov ↗ · Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)	Phase 2	Active, closed	2021-11	USA
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma NCT02979522 · ClinicalTrials.gov ↗ · Hodgkin Disease Drugs: Brentuximab Vedotin, Dacarbazine, Doxorubicin	Phase 1/2	Active, closed	2017-09	USA
A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy NCT04961840 · ClinicalTrials.gov ↗ · Constipation, Pregnancy	Observational	Active, closed	2022-01	USA
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC) NCT05721950 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC) Drug: Brigatinib	Observational	Active, closed	2024-01	China
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases NCT06076642 · ClinicalTrials.gov ↗ · Primary Immunodeficiency Diseases (PID)	Phase 3	Active, closed	2024-11	USA
A Study of CDPATH™ to Help Manage and Treat Crohn's Disease NCT04809363 · ClinicalTrials.gov ↗ · Crohn's Disease	Phase 4	Active, closed	2021-06	USA
Post-Marketing Study of Prucalopride Safety In Pregnancy NCT04869280 · ClinicalTrials.gov ↗ · Chronic Idiopathic Constipation (CIC)	Observational	Active, closed	2021-05	USA
A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome NCT06973304 · ClinicalTrials.gov ↗ · Short Bowel Syndrome	Phase 3	Active, closed	2025-06	China
A Study of NINLARO® in Chinese Adults With Multiple Myeloma NCT05013190 · ClinicalTrials.gov ↗ · Multiple Myeloma	Observational	Active, closed	2021-10	China
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) NCT05673785 · ClinicalTrials.gov ↗ · Lymphoma Drugs: Brentuximab Vedotin, Cyclophosphamide, Doxorubicin	Phase 2	Active, closed	2023-02	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Takeda trials

34 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Takeda trials

53 conditions

Crohn's Disease12 Ulcerative Colitis8Alpha1-Antitrypsin Deficiency4Cytomegalovirus (CMV)3Psoriatic Arthritis3Narcolepsy Type 13Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)3Anemia2 Myelodysplastic Syndromes2Von Willebrand Disease (VWD)2Myelofibrosis2Immune Thrombocytopenic Purpura (ITP)2Kidney Disease2Plaque Psoriasis2 Multiple Myeloma2Narcolepsy Type 22Idiopathic Hypersomnia2Short Bowel Syndrome (SBS)2Chronic Idiopathic Constipation (CIC)2Myelodysplastic Syndrome1Carcinoma, Non-Small-Cell Lung1Kidney Failure1Hereditary Angioedema (HAE)1Crohn's Disease (CD)1

By trial register

Register	Trials	Recruiting
Clinical trials in USA	62	46
Clinical trials in China	36	24
Clinical trials in UK	28	21
Clinical trials in Ireland	9	9
Clinical trials in India	5	5

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Crohn's Disease

Sponsor	Trials
AbbVie	10
Janssen-Cilag	2
Jiangsu Topcel-KH Pharmaceutical	1
Xiang Gao	1

Sponsors with the most current trials registered for this condition.

Questions about Takeda trials

How many clinical trials does Takeda sponsor?

Takeda is the lead sponsor of 77 current trials on ClinicalTrials.gov in our USA, China, UK, Ireland and India registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Takeda trials recruiting?

Yes. 55 of its 77 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Takeda testing?

Its current trials name 34 drugs and biologicals as interventions. The most frequent are Zasocitinib (11), Vedolizumab (10), Elritercept (5), Mezagitamab (4) and TAK-360 (4). The number in brackets is how many of its trials name each drug.

Does Takeda have clinical trials in Ireland?

Yes. 9 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Takeda clinical trials